How KADCYLA is thought to work

What is KADCYLA and how is it different?

KADCYLA is the first HER2-targeted treatment of its kind. It is made up of two cancer-fighting agents in one drug:

  • The monoclonal antibody trastuzumab (the same antibody in Herceptin®)
  • A chemotherapy

When you take KADCYLA, you are getting both a HER2-targeted treatment and a chemotherapy, at the same time.

  • KADCYLA is thought to bring chemotherapy inside HER2+ cells and kill them
  • KADCYLA is designed to cause less harm to normal cells, although it can still affect them. KADCYLA can cause serious side effects

How KADCYLA is thought to work

  1. Attaches to a HER2 receptor: KADCYLA is designed to find HER2+ cells and attach to them. It tells the cells to stop growing and tells the body’s immune system to destroy them.
  2. Goes inside the cell: KADCYLA also goes inside the cell to keep fighting from the inside.
  3. Breaks apart inside the cell: KADCYLA releases the chemotherapy inside the cell.
  4. Works to help kill the cell: The chemotherapy goes to work inside the cell, causing the cell to die.

KADCYLA for HER2+ early breast cancer

Learn about how well KADCYLA worked for people with HER2+ early breast cancer and what potential side effects to expect.

KADCYLA for HER2+ metastatic breast cancer

Learn about how well KADCYLA worked for people with HER2+ metastatic breast cancer and what potential side effects to expect.